Bio-medical company raises £1m

A BIOTECH business has raised $1.75m (£1.1m) from investors to allow it to take two of its fledgling therapies to clinical trial.

Blueberry Therapeutics, based at the BioHub at Alderley Park, Cheshire, is working on creating safe, effective nano-medicines which will address the growing conerns over antibiotic resistance in bacterial infection.

The funds raised will help Blueberry take two programmes, which it has been developing for several ears, to clinical testing, with the aim of gaining regulatory approval for new medicines that will significantly improve cure rates and treatment times for fungal infections.

Dr John Ridden, chief executive of Blueberry Therapeutics said: “Securing this investment is an extremely significant stepping stone in our journey to deliver new therapies to patients suffering from serious bacterial and fungal infections.”

The company was advised by the corporate team at south Manchester law firm Slater Heelis.

Partner Simon Wallwork said: “Blueberry Therapeutics continues to develop an impressive range of pharmaceutical solutions and I’m confident that this funding will enable it to create new products that will lead to positive outcomes for patients and treatment providers.”